Segment Covered
The report on global anti-obesity prescription drugs market covers segments such as, drug class, distribution
channel and age group. On the basis of drug class the global anti-obesity prescription drugs market is
categorized into orlistat, phentermine and topiramate, bupropion and naltrexone, lorcaserin and liraglutide.
On the basis of distribution channel the global anti-obesity prescription drugs market is categorized into retail
pharmacy, hospital pharmacy and online pharmacy. On the basis of age group the global anti-obesity
prescription drugs market is categorized into pediatric and adult.
Make an Enquiry
https://www.infiniumglobalresearch.com/reports/enquiry/1127
Geographic Coverage
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and
Rest of the World. In this section the key trends and market size for each geography is provided over the
period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico;
while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany,
U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the
North America region as it is the largest market in the region. The Asia-pacific region offers a substantial
potential for the market growth owing to rapid growth in markets such as India and China. Countries such as
the U.S., the U.K., and France among others have reported substantial rise in the obesity population.
Moreover, growing work stress in emerging markets of Asia-pacific is likely to cause rise in obesity cases in the
years to come over the next six years. According to the study North America followed by Europe accounted for
the largest market share in the word anti-obesity prescription drugs market in 2016 and this trend is projected
to continue over the forecast period, with increasing awareness among the people in the U.S. and Canada.
Infinium Global Research